Bellevue Group AG
Institutional InvestorSimilar funds →SEC EDGAR: CIK 1674546
Institutional-grade research for retail investors
13F Reported Value
ⓘ$4.2B
Holdings
155
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Bellevue Group AG disclosed 155 positions worth $4.2B in its Form 13F-HR for Q1 2026, led by $VRTX (VERTEX PHARMACEUTICALS INC / MA) at 7.3% of the equity portfolio, followed by $ARGX and $REGN. During the quarter the fund opened 18 new positions and exited 39 — including a new stake in $ELVN and a full exit from $FOLD. The portfolio is most concentrated in Healthcare (96.9% of disclosed assets). All figures are sourced directly from Bellevue Group AG’s Form 13F-HR filing with the SEC under CIK 1674546.
AI Fund Analysis
DiversifyingSector Allocation
HealthcareTechnologyConsumer StaplesEnergyOtherIndustrials
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
AI Quality Scored
- 76.6#101
Quality
$304.5M681,908 sh - —
Quality
$228.6M313,000 sh - 75.1#138
Quality
$215.3M278,674 sh - —
Quality
$176.2M3,584,573 sh - 77.8
Quality
$163.0M1,169,879 sh - —
Quality
$150.2M1,544,456 sh - 37.1
Quality
$136.6M1,818,665 sh - 81.4
Quality
$132.1M286,654 sh - 30.5
Quality
$131.6M6,726,144 sh - 75.9
Quality
$124.5M481,785 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 VERTEX PHARMACEUTICALS INC / MA$VRTX | 76.6#101 | $304.5M | 681,908 |
 ARGENX SE$ARGX | — | $228.6M | 313,000 |
 REGENERON PHARMACEUTICALS, INC.$REGN | 75.1#138 | $215.3M | 278,674 |
 Scholar Rock Holding Corp$SRRK | — | $176.2M | 3,584,573 |
 GILEAD SCIENCES, INC.$GILD | 77.8 | $163.0M | 1,169,879 |
 Revolution Medicines, Inc.$RVMD | — | $150.2M | 1,544,456 |
 IONIS PHARMACEUTICALS INC$IONS | 37.1 | $136.6M | 1,818,665 |
 INTUITIVE SURGICAL INC$ISRG | 81.4 | $132.1M | 286,654 |
 Viridian Therapeutics, Inc.\DE$VRDN | 30.5 | $131.6M | 6,726,144 |
 Krystal Biotech, Inc.$KRYS | 75.9 | $124.5M | 481,785 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Bellevue Group AG's 155 positions.
Showing top 10 of 155 holdings.
Sector Allocation
Healthcare
$4.1B
Technology
$98.8M
Consumer Staples
$20.6M
Energy
$2.9M
Other
$2.3M
Industrials
$2.0M
Financials
$1.4M
Consumer Discretionary
$607,059
Full Holdings — Bellevue Group AG (Q1 2026)
All 155 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $VRTX | VERTEX PHARMACEUTICALS INC / MA | $304.5M | 7.3% | +0% | 76.6 |
| 2 | $ARGX | ARGENX SE | $228.6M | 5.4% | -32% | — |
| 3 | $REGN | REGENERON PHARMACEUTICALS, INC. | $215.3M | 5.1% | +1901% | 75.1 |
| 4 | $SRRK | Scholar Rock Holding Corp | $176.2M | 4.2% | -12% | — |
| 5 | $GILD | GILEAD SCIENCES, INC. | $163.0M | 3.9% | +2118% | 77.8 |
| 6 | $RVMD | Revolution Medicines, Inc. | $150.2M | 3.6% | -69% | — |
| 7 | $IONS | IONIS PHARMACEUTICALS INC | $136.6M | 3.3% | -62% | 37.1 |
| 8 | $ISRG | INTUITIVE SURGICAL INC | $132.1M | 3.1% | -11% | 81.4 |
| 9 | $VRDN | Viridian Therapeutics, Inc.\DE | $131.6M | 3.1% | +54% | 30.5 |
| 10 | $KRYS | Krystal Biotech, Inc. | $124.5M | 3.0% | +17% | 75.9 |
| 11 |  $CRNX | Crinetics Pharmaceuticals, Inc. | $119.1M | 2.8% | NEW | 26.5 |
| 12 |  $ABT | ABBOTT LABORATORIES | $118.2M | 2.8% | -13% | 67 |
| 13 |  $NUVL | Nuvalent, Inc. | $107.9M | 2.6% | +2% | — |
| 14 |  $AMGN | AMGEN INC | $103.9M | 2.5% | +1497% | 79.5 |
| 15 |  $BSX | BOSTON SCIENTIFIC CORP | $92.0M | 2.2% | -6% | 79.9 |
| 16 |  $ELVN | Enliven Therapeutics, Inc. | $91.0M | 2.2% | NEW | — |
| 17 |  $IMCR | Immunocore Holdings plc | $84.3M | 2.0% | +0% | — |
| 18 |  $MDT | Medtronic plc | $83.0M | 2.0% | +25% | — |
| 19 |  $ALNY | ALNYLAM PHARMACEUTICALS, INC. | $77.6M | 1.9% | -47% | 60.9 |
| 20 |  $RLAY | Relay Therapeutics, Inc. | $77.6M | 1.9% | -7% | 12.7 |
| 21 |  $SYK | STRYKER CORP | $71.4M | 1.7% | -40% | 69.8 |
| 22 |  $PCVX | Vaxcyte, Inc. | $69.2M | 1.6% | NEW | — |
| 23 |  $VERA | Vera Therapeutics, Inc. | $68.8M | 1.6% | +1% | — |
| 24 |  $EW | Edwards Lifesciences Corp | $67.2M | 1.6% | -20% | 67.6 |
| 25 |  $DMRA | Damora Therapeutics, Inc. | $59.5M | 1.4% | NEW | — |
| 26 |  $TNGX | Tango Therapeutics, Inc. | $50.2M | 1.2% | -39% | 26.9 |
| 27 |  $IDXX | IDEXX LABORATORIES INC /DE | $50.1M | 1.2% | -6% | 73.6 |
| 28 |  $RARE | Ultragenyx Pharmaceutical Inc. | $49.9M | 1.2% | NEW | 31 |
| 29 |  $DXCM | DEXCOM INC | $49.5M | 1.2% | -7% | 77.9 |
| 30 |  $JBIO | Jade Biosciences, Inc. | $49.2M | 1.2% | +5% | — |
| 31 |  $EWTX | Edgewise Therapeutics, Inc. | $48.1M | 1.1% | +0% | — |
| 32 |  $UNH | UNITEDHEALTH GROUP INC | $40.1M | 0.9% | -15% | 66.8 |
| 33 |  $DHR | DANAHER CORP /DE/ | $38.3M | 0.9% | +4% | 63.9 |
| 34 |  $CLDX | Celldex Therapeutics, Inc. | $38.1M | 0.9% | -67% | 13.2 |
| 35 |  $RMD | RESMED INC | $35.8M | 0.8% | -1% | 79.8 |
| 36 |  $PODD | INSULET CORP | $34.3M | 0.8% | -12% | 70.4 |
| 37 |  $TMO | THERMO FISHER SCIENTIFIC INC. | $31.7M | 0.8% | -1% | 63.7 |
| 38 |  $LLY | ELI LILLY & Co | $31.2M | 0.7% | -0% | 89.3 |
| 39 |  $GEHC | GE HealthCare Technologies Inc. | $29.7M | 0.7% | -2% | 58.2 |
| 40 |  $IRON | Disc Medicine, Inc. | $29.4M | 0.7% | NEW | — |
| 41 |  $JNJ | JOHNSON & JOHNSON | $29.1M | 0.7% | -6% | 72.8 |
| 42 |  $ANNX | Annexon, Inc. | $28.6M | 0.7% | +0% | — |
| 43 |  $CI | Cigna Group | $26.2M | 0.6% | -11% | 66.8 |
| 44 |  $ORKA | Oruka Therapeutics, Inc. | $24.9M | 0.6% | NEW | — |
| 45 |  $MRK | Merck & Co., Inc. | $24.9M | 0.6% | +124% | 70.9 |
| 46 |  $ALGN | ALIGN TECHNOLOGY INC | $23.9M | 0.6% | -1% | 58.2 |
| 47 |  $STE | STERIS plc | $22.1M | 0.5% | -2% | — |
| 48 |  $GMED | GLOBUS MEDICAL INC | $21.3M | 0.5% | -6% | 77.6 |
| 49 |  $GLUE | Monte Rosa Therapeutics, Inc. | $20.6M | 0.5% | NEW | 18.1 |
| 50 |  $ABBV | AbbVie Inc. | $20.3M | 0.5% | -31% | 59.3 |
| 51 |  $COO | COOPER COMPANIES, INC. | $19.5M | 0.5% | -7% | 55.8 |
| 52 |  $MCK | MCKESSON CORP | $19.3M | 0.5% | -11% | 63.7 |
| 53 |  $BDX | BECTON DICKINSON & CO | $19.2M | 0.5% | -54% | 50.7 |
| 54 |  $HCA | HCA Healthcare, Inc. | $17.9M | 0.4% | -14% | 70.5 |
| 55 |  $GKOS | GLAUKOS Corp | $15.7M | 0.4% | -44% | 39.2 |
| 56 |  $ELV | Elevance Health, Inc. | $15.4M | 0.4% | -25% | 59.4 |
| 57 |  $ZBH | ZIMMER BIOMET HOLDINGS, INC. | $14.1M | 0.3% | -35% | 64.9 |
| 58 |  $PRCT | PROCEPT BioRobotics Corp | $12.6M | 0.3% | -3% | 34.8 |
| 59 |  $LIVN | LivaNova PLC | $11.8M | 0.3% | NEW | — |
| 60 |  $HUM | HUMANA INC | $11.2M | 0.3% | -12% | 82 |
| 61 |  $TMDX | TransMedics Group, Inc. | $10.1M | 0.2% | +3% | 70.1 |
| 62 |  $VEEV | VEEVA SYSTEMS INC | $9.9M | 0.2% | -30% | 77.8 |
| 63 |  $CNC | CENTENE CORP | $8.5M | 0.2% | -5% | 52.7 |
| 64 |  $TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | $7.5M | 0.2% | -24% | — |
| 65 |  $THC | TENET HEALTHCARE CORP | $7.2M | 0.2% | -5% | 66.6 |
| 66 |  $TXG | 10x Genomics, Inc. | $7.0M | 0.2% | +2% | 44.1 |
| 67 |  $CVS | CVS HEALTH Corp | $6.4M | 0.1% | -18% | 51.3 |
| 68 |  $NTRA | Natera, Inc. | $6.3M | 0.1% | -43% | 46.4 |
| 69 |  $WAY | Waystar Holding Corp. | $6.2M | 0.1% | +6% | 71.4 |
| 70 |  $MDLN | Medline Inc. | $6.1M | 0.1% | +16% | — |
| 71 |  $INSP | Inspire Medical Systems, Inc. | $5.1M | 0.1% | -1% | 46 |
| 72 |  $PRVA | Privia Health Group, Inc. | $4.7M | 0.1% | -49% | 49.4 |
| 73 |  $PEN | Penumbra Inc | $4.0M | 0.1% | -91% | 69.7 |
| 74 |  $RNA | Avidity Biosciences, Inc. | $3.5M | 0.1% | -90% | 22.3 |
| 75 |  $PFE | PFIZER INC | $3.0M | 0.1% | +89% | 69 |
| 76 |  $ILMN | ILLUMINA, INC. | $2.5M | 0.1% | -12% | 62.5 |
| 77 |  $KMTS | KESTRA MEDICAL TECHNOLOGIES, LTD. | $2.3M | 0.1% | -0% | 30.8 |
| 78 |  $OMDA | Omada Health, Inc. | $2.0M | 0.1% | -11% | 45.5 |
| 79 |  $BBIO | BridgeBio Pharma, Inc. | $1.9M | 0.0% | +5% | 31.7 |
| 80 |  $BNTX | BioNTech SE | $1.9M | 0.0% | -52% | — |
| 81 |  $RPRX | Royalty Pharma plc | $1.8M | 0.0% | +190% | — |
| 82 |  $SPY | SPDR S&P 500 ETF TRUST | $1.8M | 0.0% | -13% | — |
| 83 |  $INSM | INSMED Inc | $1.6M | 0.0% | -28% | 29.4 |
| 84 |  $MDGL | MADRIGAL PHARMACEUTICALS, INC. | $1.6M | 0.0% | +5% | 25.4 |
| 85 |  $MASI | MASIMO CORP | $1.6M | 0.0% | -91% | 47.1 |
| 86 |  $PTGX | Protagonist Therapeutics, Inc | $1.5M | 0.0% | -13% | 24.8 |
| 87 |  $UTHR | UNITED THERAPEUTICS Corp | $1.2M | 0.0% | -47% | 80.1 |
| 88 |  $ONC | BeOne Medicines Ltd. | $1.1M | 0.0% | +102% | — |
| 89 |  $PHR | Phreesia, Inc. | $1.1M | 0.0% | -29% | 53.2 |
| 90 |  $ADPT | Adaptive Biotechnologies Corp | $1.1M | 0.0% | -74% | 35.2 |
| 91 |  $BMY | BRISTOL MYERS SQUIBB CO | $1.0M | 0.0% | -75% | 70.1 |
| 92 |  $EHC | Encompass Health Corp | $950,759 | 0.0% | -49% | 68.9 |
| 93 |  $NAMS | NewAmsterdam Pharma Co N.V. | $885,429 | 0.0% | -24% | — |
| 94 |  $AAPL | Apple Inc. | $842,583 | 0.0% | +0% | 76.1 |
| 95 |  $BLLN | BillionToOne, Inc. | $833,133 | 0.0% | -0% | — |
| 96 |  $MLYS | Mineralys Therapeutics, Inc. | $795,742 | 0.0% | +48% | — |
| 97 |  $EQNR | EQUINOR ASA | $741,581 | 0.0% | NEW | — |
| 98 |  $XOM | EXXON MOBIL CORP | $741,414 | 0.0% | NEW | 61.8 |
| 99 |  $BP | BP PLC | $735,268 | 0.0% | NEW | — |
| 100 |  $SHEL | Shell plc | $729,492 | 0.0% | NEW | — |
| 101 |  $BBNX | Beta Bionics, Inc. | $722,963 | 0.0% | -0% | 22.8 |
| 102 |  $BIIB | BIOGEN INC. | $669,704 | 0.0% | +2% | 65.6 |
| 103 |  $LEGN | Legend Biotech Corp | $649,178 | 0.0% | -44% | 44.2 |
| 104 |  $CSCO | CISCO SYSTEMS, INC. | $620,720 | 0.0% | +0% | 72.3 |
| 105 |  $NBIX | NEUROCRINE BIOSCIENCES INC | $612,064 | 0.0% | -100% | 75.4 |
| 106 |  $BABA | Alibaba Group Holding Ltd | $589,662 | 0.0% | +0% | — |
| 107 |  $CYTK | CYTOKINETICS INC | $582,710 | 0.0% | -4% | 28 |
| 108 |  $CERT | Certara, Inc. | $566,819 | 0.0% | +0% | 47 |
| 109 |  $PRAX | Praxis Precision Medicines, Inc. | $566,088 | 0.0% | NEW | — |
| 110 |  $PG | PROCTER & GAMBLE Co | $563,316 | 0.0% | +0% | 72.9 |
| 111 |  $MA | Mastercard Inc | $549,626 | 0.0% | +0% | 81.7 |
| 112 |  $COR | Cencora, Inc. | $539,064 | 0.0% | +229% | 59.6 |
| 113 |  $AXSM | Axsome Therapeutics, Inc. | $537,653 | 0.0% | -88% | 36.6 |
| 114 | — | VANECK ETF TRUST | $527,678 | 0.0% | -63% | — |
| 115 |  $AGMB | Agomab Therapeutics NV | $524,500 | 0.0% | NEW | — |
| 116 |  $BLK | BlackRock, Inc. | $432,770 | 0.0% | +0% | 70.3 |
| 117 |  $V | VISA INC. | $423,136 | 0.0% | +0% | 83.5 |
| 118 |  $CNTA | Centessa Pharmaceuticals plc | $358,672 | 0.0% | NEW | — |
| 119 |  $DNLI | Denali Therapeutics Inc. | $341,107 | 0.0% | +149% | — |
| 120 |  $GPCR | Structure Therapeutics Inc. | $327,905 | 0.0% | -95% | — |
| 121 |  $JD | JD.com, Inc. | $325,270 | 0.0% | +0% | — |
| 122 |  $ALKS | Alkermes plc. | $313,643 | 0.0% | +35% | — |
| 123 |  $GRMN | GARMIN LTD | $306,485 | 0.0% | -23% | — |
| 124 |  $SMMT | Summit Therapeutics Inc. | $300,668 | 0.0% | +11% | — |
| 125 |  $ACN | Accenture plc | $297,435 | 0.0% | +0% | — |
| 126 |  $ADBE | ADOBE INC. | $291,696 | 0.0% | +0% | 80.4 |
| 127 |  $AMZN | AMAZON COM INC | $281,789 | 0.0% | -62% | 74.6 |
| 128 |  $TVTX | Travere Therapeutics, Inc. | $264,389 | 0.0% | +133% | 39.2 |
| 129 |  $HALO | HALOZYME THERAPEUTICS, INC. | $249,278 | 0.0% | NEW | 81.2 |
| 130 |  $OLMA | Olema Pharmaceuticals, Inc. | $245,165 | 0.0% | +321% | — |
| 131 |  $CRSP | CRISPR Therapeutics AG | $238,611 | 0.0% | +167% | 4.5 |
| 132 |  $TEM | Tempus AI, Inc. | $223,839 | 0.0% | +4% | 38.2 |
| 133 |  $CAH | CARDINAL HEALTH INC | $182,361 | 0.0% | -89% | 58.6 |
| 134 |  $PTCT | PTC THERAPEUTICS, INC. | $131,832 | 0.0% | -71% | 80 |
| 135 |  $IQV | IQVIA HOLDINGS INC. | $126,200 | 0.0% | -98% | 59.7 |
| 136 |  $ASND | Ascendis Pharma A/S | $122,599 | 0.0% | -98% | 41.5 |
| 137 |  $ABVX | Abivax S.A. | $116,695 | 0.0% | NEW | — |
| 138 |  $CAI | Caris Life Sciences, Inc. | $114,754 | 0.0% | +0% | 32 |
| 139 |  $ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $96,872 | 0.0% | -87% | 74.4 |
| 140 |  $GOOG | Alphabet Inc. | $90,294 | 0.0% | -85% | 80.2 |
| 141 |  $RYTM | RHYTHM PHARMACEUTICALS, INC. | $88,362 | 0.0% | -86% | 30.3 |
| 142 |  $A | AGILENT TECHNOLOGIES, INC. | $75,683 | 0.0% | +90% | 64.6 |
| 143 |  $LH | LABCORP HOLDINGS INC. | $74,707 | 0.0% | -95% | 54.8 |
| 144 |  $NVDA | NVIDIA CORP | $71,155 | 0.0% | -90% | 90.2 |
| 145 |  $MSFT | MICROSOFT CORP | $63,669 | 0.0% | -87% | 83.7 |
| 146 |  $ZTS | Zoetis Inc. | $63,006 | 0.0% | -27% | 72.6 |
| 147 |  $BBOT | BridgeBio Oncology Therapeutics, Inc. | $62,489 | 0.0% | NEW | — |
| 148 |  $INCY | INCYTE CORP | $45,742 | 0.0% | -90% | 81.2 |
| 149 |  $MTD | METTLER TOLEDO INTERNATIONAL INC/ | $45,403 | 0.0% | -5% | 68.8 |
| 150 |  $WVE | Wave Life Sciences Ltd. | $38,142 | 0.0% | -100% | — |
| 151 |  $ORCL | ORACLE CORP | $28,098 | 0.0% | -6% | 67.2 |
| 152 |  $DGX | QUEST DIAGNOSTICS INC | $25,673 | 0.0% | -98% | 69.1 |
| 153 |  $QCOM | QUALCOMM INC/DE | $25,370 | 0.0% | -6% | 81.9 |
| 154 |  $RXRX | RECURSION PHARMACEUTICALS, INC. | $14,205 | 0.0% | -6% | 13.6 |
| 155 |  $QGEN | QIAGEN N.V. | $9,730 | 0.0% | NEW | — |
New Positions (18)
$ELVN Enliven Therapeutics, Inc.$91.0M$PCVX Vaxcyte, Inc.$69.2M$DMRA Damora Therapeutics, Inc.$59.5M$IRON Disc Medicine, Inc.$29.4M$ORKA Oruka Therapeutics, Inc.$24.9M$GLUE Monte Rosa Therapeutics, Inc.$20.6M$LIVN LivaNova PLC$11.8M$EQNR EQUINOR ASA$741,581$XOM EXXON MOBIL CORP$741,414$BP BP PLC$735,268$SHEL Shell plc$729,492$PRAX Praxis Precision Medicines, Inc.$566,088$AGMB Agomab Therapeutics NV$524,500$CNTA Centessa Pharmaceuticals plc$358,672$HALO HALOZYME THERAPEUTICS, INC.$249,278Exited Positions (39)
$FOLD AMICUS THERAPEUTICS, INC.
$MAZE Maze Therapeutics, Inc.
$CDNA CareDx, Inc.
$MOH MOLINA HEALTHCARE, INC.
$ICLR ICON PLC
$BMRN BIOMARIN PHARMACEUTICAL INC
$BTSG BrightSpring Health Services, Inc.
$NEO NEOGENOMICS INC
$AVTR Avantor, Inc.
$BEAM Beam Therapeutics Inc.
$AZN ASTRAZENECA PLC
$VKTX Viking Therapeutics, Inc.
$ROIV Roivant Sciences Ltd.
$BKD Brookdale Senior Living Inc.
$SIBN SI-BONE, Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
Berkshire HathawayBridgewater AssociatesCitadel AdvisorsRenaissance TechnologiesTwo Sigma InvestmentsDE Shaw & CoMillennium ManagementAQR Capital ManagementPoint72 Asset ManagementTiger Global ManagementVanguard GroupBlackRock
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Bellevue Group AG including:
Full 13F portfolio with all holdings
Quarter-over-quarter position changes
Accumulation & distribution patterns
Sector allocation breakdown
Historical portfolio evolution
New positions & complete exits
Concentration analysis
Peer comparison with similar funds
AI-powered portfolio insights
Track Bellevue Group AG's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Bellevue Group AG and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
Passwordless sign-in · Payments by Stripe · Auth by Clerk
AI-Powered Hedge Fund Analysis: Bellevue Group AG
13F Pro is an AI hedge fund tracker and stock research platform. For Bellevue Group AG (SEC CIK: 1674546), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Bellevue Group AG's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.